Relationship of Na-K-ATPase inhibitors to blood-pressure regulation in continuous ambulatory peritoneal dialysis and hemodialysis

Journal of the American Society of Nephrology

Volumn 7, Issue 3, 1996, Pages 454-463

  Weiler, Elmar W J ^c   Saldanha, Leopoldo F ^c   Khalil Manesh, Farhad ^c   Prins, Bruce A ^a   Purdy, Ralph E ^a   Gonick, Harvey C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c NONE

Author keywords

Continuous ambulatory peritoneal dialysis (CAPD); Dialysis; Enzyme inhibitors; Hypertension; Vasopressors

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM);

ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; ENZYME INHIBITION; HEMODIALYSIS; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

EID: 0029942548     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Saldanha L, Weiler E, Gonick H: Effect of CAPD on blood pressure control. Am J Kidney Dis 1993;21:184-188.
2. Young M, Nolph K, Dutton S, et al.: Antihypertensive drug requirements in continuous ambulatory peritoneal dialysis. Perit Dial Bull 1984;4:86-88.
3. Cannata J, Isles C, Briggs J, et al.: Comparison of blood pressure control during hemodialysis and CAPD. Dial Transplant 1986; 15: 675-679.
4. Chan M, Chuah P, Sweny P, et al.: Three years' experience of continuous ambulatory peritoneal dialysis. Lancet 1981;1:1409-1412.
5. Gilmour J, Wu G, Khanna R, et al.: Long-term continuous ambulatory peritoneal dialysis. Perit Dial Bull 1985: 112-118.
6. Kurtz S, Wong V, Anderson C, et al.: Continuous ambulatory peritoneal dialysis. Three years' experience at the Mayo Clinic. Mayo Clin Proc 1983;58:633-639.
7. Suzuki N, Matsumoto H, Miyauchi T, et al.: Endothelin-3 concentrations in human plasma: The increased concentrations in patients undergoing haemodialysis. Biochem Biophys Res Commun 1990;169:809-815.
8. Koyama H, Tabata T, Nishizawa Y, et al.: Plasma endothelin levels in patients with uremia. Lancet 1989;1:991-992.
9. Deray G, Carayon A, Maistre G, et al.: Endothelin in chronic renal failure. Nephrol Dial Transplant 1992;7: 300-305.
10. Saito Y, Kazuwa N, Shirakami G, et al.: Endothelin in patients with chronic renal failure. J Cardiovasc Pharmacol 1991;17[Suppl 7]:S437-S439.
11. Stockenhuber F, Gottsauner-Wolf M, Marosi L, et al.: Plasma levels of endothelin in chronic renal failure and after renal transplantation: impact on hypertension and cyclosporin A-associated nephrotoxicity. Clin Sci 1992; 59:255-258.
12. Warrens A, Cassidy M, Takahashi K, et al.: Endothelin in renal failure. Nephrol Dial Transplant 1990;5:418-422.
13. Shichiri M, Hirata Y, Ando K, Emori T, et al.: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990;15:493-496.
14. Elias A, Vaziri N, Masky M: Plasma norepinephrine, epinephrine and dopamine levels in end-stage renal disease. Arch Intern Med 1985;145:1013-1015.
15. Zucalla A, Chiarini C, Esposito E, et al.: Plasma noradrenaline and blood pressure in uremia. J Clin Hypertens 1985;2:161-169.
16. Zabetakis P, Kumar D, Gleim G, et al.: Increased levels of plasma renin, aldosterone, catecholamines and vasopressin in chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Nephrol 1987;28:147-151.
17. Dimitriadis A, Antonio S, Malaka E: Serotonin in the control of blood pressure and ultrafiltration in CAPD. Adv Perit Dial 1990;6:220-223.
18. Kelly R O'Hara D, Mitch W: Endogenous digitalis-like factors in hypertension and chronic renal insufficiency. Kidney Int 1986;30:723-729.
19. Krzesinski J, Godon J, Rorive G: Arguments for the presence of a Na-K-ATPase pump inhibitor in the plasma of uremic and essential hypertension patients. Clin Exp Hypertens [A]1985;7:721-733.
20. Stokes G, Norris L: Effect of dialysis on circulating Na-K-ATPase inhibitor in uremic patients. Nephron 1990;54:127-133.
21. Vasdev S, Johnson E, Longerich L: Plasma endogenous digitalis-like factors in healthy individuals and in dialysis-dependent and kidney transplant patients. Clin Nephrol 1987;27:169-174.
22. Graves S, Glatter K, Lazarus J, Williams G, Hollenberg N: Volume expansion in renal failure patients: A paradigm for a clinically relevant (Na,K)ATPase inhibitor. J Cardiovasc Pharmacol 1993;[Suppl 2]:S854-S857.
23. Krzesinski J, Du F, Pequeux M, Rorive G: Plasma Na-K ATPase inhibitor activity and intracellular ions during hemodialysis. Int J Artif Organs 1993;16:23-30.
24. Brearley CJ, Aronson JK, Boon NA, Raine AEG: Effects of haemodialysis and continuous ambulatory peritoneal dialysis on abnormalities of ion transport in vivo in patients with chronic renal failure. Clin Sci 1993;85: 725-731.
25. Gonick H, Weiler E, Khalil-Manesh F, Weber M: Predominance of high molecular weight plasma Na-K-ATPase inhibitor in essential hypertension. Am J Hypertens 1993;6:680-687.
26. Klein E, Autian J, Bower J, et al.. Evaluation of Hemodialyzers and Dialysis Membranes. US Department of Health Education and Welfare, National Institute of Health [DHEW Publication No. (NIH) 77-1294]. 1977.
27. Rippe B, Stelin G: Simulations of peritoneal solute transport during CAPD. Application of two-pore formalism. Kidney Int 1989;35:1234-1244.
28. Fiske C, Subbarow Y: The colorimetric determination of phosphorus. J Biol Chem 1925;66:375-400.
29. Weiler E, Tuck M, Gonick H: Observations on the "cascade" of Na-K-ATPase inhibitory and digoxin-like immunoreactive material in human urine: Possible relevance to essential hypertension. Clin Exp Hypert Theory Prac 1985;7:809-836.
30. Laemmli U: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 277:680-685.
31. Purdy R, Murray D, Stupecky G: Receptors for 5-HT in rabbit blood vessels: activation of adrenoreceptors in rabbit thoracic aorta. J Pharmacol Exp Ther 1987;240: 535-541.
32. Gault MH, Vasdev SC, Longerich L, Purchase L, et al.: Heparin, fatty acids ad sodium, potassium- ATPase inhibition by plasma factors during hemodialysis. Nephron 1992;60:292-301.
33. Lazarus J, Hampers C, Merrill J: Hypertension and chronic renal failure: Treatment with hemodialysis and nephrectomy. Arch Intern Med 1974;133:1059-1066.
34. Buckalew V, Nelson D: Natriuretic and sodium transport activity in plasma of volume-expanded dogs. Kidney Int 1974;5:12-22.
35. Gonick H, Kramer H, Paul W, Lu E: Circulating inhibitor of sodium-potassium-activated adenosine triphosphatase after expansion of extracellular fluid volume in rats. Clin Sci Mol Med 1977;53:329-334.
36. +)ATPase associated with essential hypertension. Nature 1982;300:650-652.
37. Huot S, Pamnani M, Clough D, et al.: Sodium-potassium pump activity in reduced renal mass hypertension. Hypertension (Dallas) 1983;5:94-100.
38. MacGregor G, Fenton S, Alaghband-Zadeh J, et al.: Evidence for a raised concentration of a circulating transport inhibitor in essential hypertension. Br Med J 1981;283:1355-1357.
39. Edmondson R, MacGregor G: Leucocyte cation transport in essential hypertension: its relationship to the renin-angiotensin system. Br Med J 1981;282:1267-1269.
40. Haddy F, Pamnani M, Clough D: Humoral factors and the sodium-potassium pump in volume-expanded hypertension. Life Sci 1979;24:2105-2118.
41. de Wardener H, MacGregor G: The relationship of a circulating sodium transport inhibitor (the natriuretic hormone?) to hypertension. Medicine (Baltimore) 1983; 62:310-326.
42. Blaustein M: Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. Am J Physiol 1977;232:C165-C173.
43. Hillyard S, Lu E, Gonick H: Further characterization of the natriuretic factor derived from kidney tissue of volume-expanded rats. Effects on short-circuit current and sodium-potassium-adenosine triphosphatase activity. Circ Res 1976;38:250-255.
44. Kelly R, O'Hara D, Canessa M, Mitch W, Smith T: Characterization of digitalis-like factors in human plasma: Interactions with Na-K-ATPase and cross-reactivity with cardiac glycoside-specific antibodies. J Biol Chem 1985;260:11396-11405.
45. Devynck M, Pernallet M, Deray G, et al.: Circulating inhibitor of sodium active transport in essential hypertension and volemic expansion. Arch Mal Coeur Vaiss 1985;78:1691-1695.
46. Gruber KA, Whitaker JM, Buckalew VM: Endogenous digitalis-like substance in plasma of volume-expanded dogs. Nature 1980;287:743-745.
47. Sealey J, Kirschman J, Laragh J: Natriuretic activity in plasma and urine of salt-loaded man and sheep. J Clin Invest 1969;48:2210-2224.
48. Nardi R, Carretta R, Sawa H, Bianchi M, Fernandes M: Characteristic variation in electrophoretic pattern of plasma proteins in essential hypertension. Lancet 1980; 2:182-183.
49. Cloix JF, Devynck M-A, Funck-Brentano JL, Meyer P: Plasma protein changes in primary hypertension in humans and rats. Hypertension 1983;5:128-134.
50. Van de Voorde A, De Broe M, Pollet D, Rutsaert R, Mouwen E: Isolation of a plasma protein in patients with essential hypertension. Biochem Biophys Res Commun 1983;111:1015-1021.
51. Weiler E, Khalil-Manesh F, Horn E, Amin D, Shah PK, Gonick HC: Circulating high molecular weight form of Na-K-ATPase inhibitor - Changes in Disease [Abstract]. Clin Res 1986;34:90A.
52. Gonick HC, Weiler E, Khalil-Manesh F, Prins B, Purdy R, Sensharma DK: Hypertension-associated protein (HAP): Carrier for natriuretic hormone? XIIth International Congress of Nephrology, Jerusalem, Israel, June 13-18, 1993.
53. Gonick H, Weiler E, Prins B, Purdy R: Comparison of low-molecular-weight plasma and urine Na-K-ATPase inhibitors/hypertensive factors. J Cardiovasc Pharmacol 1993;22[Suppl 2]:S69-S71.
54. Glatter KA, Graves SW, Hollenberg NK, et al.: Sustained volume expansion and [Na,K]ATPase inhibition in chronic renal failure. Am J Hypertens 1994;7:1016-1025.
55. Sebekova K, Raucinova M, Dzurik R: Serotonin metabolism in patients with decreased renal function. Nephron 1989;53:229-232.
56. Kerr PG, Argiles A, Mion C: Whole blood serotonin levels are markedly elevated in patients on dialytic therapy. Am J Nephrol 1992;12:14-18.
57. Weiler E, Gonick H, Prins B, Purdy R, Weber M: Characterization of a low molecular weight Na-K-ATPase inhibitor of urinary origin. Am J Med Sci 1994;307:27-35.